Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta
NCT02303873Phase 4Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2007
- Primary completion
- Jul 2011
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of alendronate in osteogenesis imperfecta (OI), sponsored by Peking Union Medical College Hospital. Primary endpoints: Areal Bone Mineral Density at 36 months and Annual Clinical Fracture Incidence at 36 months. Started Mar 2007; status: completed.
02
Drugs
alendronate
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT02303873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303873.